<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668835/" ref="ordinalpos=1712&amp;ncbi_uid=4966040&amp;link_uid=PMC3668835" image-link="/pmc/articles/PMC3668835/figure/F4/" class="imagepopup">Figure 4. <span class="highlight" style="background-color:">Signaling</span> connected with the PI3K/Akt/mTOR <span class="highlight" style="background-color:">pathway</span> and altered in SI-NETs..  From: The genomic landscape of small intestine neuroendocrine tumors. </a></div><br /><div class="p4l_captionBody">Cancer therapeutics target multiple proteins in connected signaling cascades. Candidate therapeutically actionable genome alterations were noted in 72% of SI-NET patients. FLT3, fms-like tyrosine kinase receptor 3.</div></div>